There are three weeks left to apply for the National Cancer Institute (NCI) Immunotherapy Fellowship. This opportunity provides exposure to multiple clinical cancer immunotherapeutic approaches. Be sure to apply for this one-year visiting fellowship! Applications are due Aug. 19. Apply here: https://lnkd.in/gmD2gPBq #Fellowship #IO #SITC
Society for Immunotherapy of Cancer (SITC)
Non-profit Organization Management
Milwaukee, Wisconsin 17,574 followers
SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.
About us
The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. sitc_log_color.png Established in 1984, SITC, a 501(c)(3) not-for-profit organization, serves scientists, clinicians, academicians, patients, patient advocates, government representatives and industry leaders from around the world. Through educational programs that foster scientific exchange and collaboration, SITC aims to one day make the word “cure” a reality for cancer patients everywhere. Currently, SITC has more than 2,000 members who represent 22 medical specialties in 42 countries around the world. Through emphasis on high-caliber scientific meetings; dedication to education and outreach activities; focus on initiatives of major importance in the field; and commitment to collaborations with like-minded domestic and international organizations, government and regulatory agencies, associations and patient advocacy groups, SITC brings together all aspects of the cancer immunology and immunotherapy community. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.
- Website
-
https://www.sitcancer.org
External link for Society for Immunotherapy of Cancer (SITC)
- Industry
- Non-profit Organization Management
- Company size
- 11-50 employees
- Headquarters
- Milwaukee, Wisconsin
- Type
- Nonprofit
- Founded
- 1984
- Specialties
- Cancer, Oncology, Immunotherapy, Networking, T Cells, Vaccines, Cytokines, Monoclonal Antibodies, Clinical Trials, Biomarkers, Personalized Medicine, Cancer Stem Cells, Phase I, Phase II, Phase III, Human Immunology, Tumor Microenvironment, and Targeted Therapeutics
Locations
-
Primary
555 E. Wells Street
Suite 1100
Milwaukee, Wisconsin 53202, US
Employees at Society for Immunotherapy of Cancer (SITC)
-
Joseph Murphy
Founder and President at immunePCS, LLC
-
Daniel Chen, M.D. Ph.D.
Physician-Scientist, Cancer Immunotherapy
-
Angela Kilbert
Director of Scientific Publications at the Society for Immunotherapy of Cancer
-
Zhen Su, MD MBA
Physician Scientist, Entrepreneur and CEO at Marengo Therapeutics
Updates
-
The SITC melanoma clinical practice guideline (CPG) rapid update v3.1 addresses lifileucel as an additional treatment option to be considered for patients with advanced melanoma that have progressed on prior therapies. Visit the SITC melanoma CPG as published in Journal for ImmunoTherapy of Cancer to view the current recommendations, including this and other rapid updates to the guideline! https://lnkd.in/dj6VTPga Rapid updates are made possible through SITC’s Living Guideline protocols. For more information on Living Guidelines, visit our website. https://lnkd.in/grZ7iFrh Thank you to all the members of the SITC melanoma CPG expert panel for their contributions. Ryan Sullivan, Harvard Medical School, Massachusetts General Hospital, Anna Pavlick, MD, MBA, Weill Cornell Medicine, Charlotte Ariyan, Memorial Sloan Kettering Cancer Center, Beth Buchbinder, Dana-Farber Cancer Institute, Diwakar Davar, UPMC Hillman Cancer Center, Geoffrey Gibney, Georgetown Lombardi Comprehensive Cancer Center, Omid Hamid, The Angeles Clinic & Research Institute, Inc., Tina J. Hieken, Mayo Clinic, Benjamin Izar, Columbia University, Douglas B. Johnson, Vanderbilt University Medical Center, Rajan P Kulkarni, Oregon Health & Science University, Jason Luke, UPMC Hillman Cancer Center, Tara C. Mitchell, University of Pennsylvania, Meghan J. Mooradian, Massachusetts General Hospital Cancer Center, Krista Rubin, Massachusetts General Hospital, April K.S. Salama MD, Duke University, Keisuke Shirai, Dartmouth-Hitchcock Medical Center, Janis M. Taube, The Johns Hopkins University School of Medicine, Hussein Tawbi, The University of Texas MD Anderson Cancer Center, Keith Tolley, AIM at Melanoma, Caressa Valdueza, Weill Cornell Medicine, Sarah A. Weiss, Rutgers Cancer Institute and Michael K. Wong, The University of Texas MD Anderson Cancer Center. #SITCGuidelines #Melanoma #Immunotherapy
-
-
Save your spot at the #SITC Immuno-oncology Drug Development Summit in Boston on Sept. 30–Oct. 1, 2024. This two-day program will explore the landscape of state-of-the-art modern #IO drug development, including study design, regulatory pathways and emerging technologies. Day 2 Session Highlight: Session V: Investor Perspectives Moderator: Luisa Salter-Cid, PhD - Flagship Pioneering. This session will consist of: 1. Investor Perspective with Jakob Dupont, MD MA - Sofinnova Investments 2. Panel Discussion with Christiana Bardon M.D. – MPM BioImpact, Jakob Dupont, MD - Safinnova Investments, Daina Graybosch, PhD – Leerink Partners, Jason Ruth, PhD – MRL Ventures, Asish Xavier, PhD, MBA - Venture Investments Ltd Register for the IO Drug Development Summit: lnkd.in/gexYHh5e #immunotherapy
-
-
Take advantage of this opportunity to present and discuss your hottest new research with luminaries in the cancer immunotherapy field and more than 6,000 colleagues from across the globe at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting & Pre-Conference Programs (SITC 2024). All accepted Late-breaking Abstracts – Clinical Only will have the opportunity to present a poster in the Poster Hall and are published in the Journal for ImmunoTherapy of Cancer (JITC). LBAs must address interventional clinical trials in humans. The deadline to submit research for Late-breaking Abstracts is 5 p.m. PDT on Sept.12, 2024. Submit a Late-breaking Abstract to #SITC24: https://lnkd.in/gXTt-BYs
-
-
Calling all Young Investigators & Clinicians! Ready to unlock the next level in cancer immunotherapy? Don't miss your chance to join the Cancer Immunotherapy Winter School! We're thrilled to offer 5 travel awards with up to $1,000 reimbursement for eligible expenses Expand your knowledge, network with peers, and ignite your career in cancer research. Register now at sitcancer.org/WinterSchool and seize the opportunity to make a difference! Travel Award Deadline is Aug. 5, 2024 #CancerImmunotherapy #YoungInvestigators #Clinicians Program Organizers: Kristin Anderson from University of Virginia Chrystal Paulos from Winship Cancer Institute of Emory University Daniel Powell Jr., PhD from University of Pennsylvania. Program Advisor: Christian Capitini, MD from University of Wisconsin-Madison
-
-
Deadline Alert: Only One Week Left to Apply! Don't miss your chance to join the #SITC SCION 2025 program. Connect with expert faculty and patient advocates to develop clinical trial protocols in this unique workshop. Dive into cancer immunotherapy, covering clinical trial endpoints, biomarker development, combination strategies, cost estimation, regulatory pathways, and oncology-specific challenges. Join us in vibrant Austin, TX, from Feb. 11–14, 2025. Open to individuals from academic, non-profit, or for-profit organizations, including the pharmaceutical and biotechnology sectors. Professionals with related degrees are also welcome. Apply by August 5, 2024, at https://lnkd.in/gJaAbds6 Organizers: Codruta Chiuzan, PhD from Northwell Health Deborah Collyar from Patient Advocates in Research Isabella (Bella) Glitza Oliva from MD Anderson Cancer Center Yana Najjar, MD from UPMC Hillman Cancer Center Chris Takimoto, MD, PhD from IGM Biosciences, Inc. Program Advisors: Elizabeth Garrett-Mayer, PhD, FSCT from American Society of Clinical Oncology (ASCO)
-
-
SITC is pleased to honor our very own Andrea Kunz for receiving the Pedro J. Romero Service to JITC Award. Congratulations and thank you for your significant contributions to JITC. LEARN MORE: https://lnkd.in/gKyiHWYb
-
-
Define the impact of glycans on anti-tumor immunity and immune resistance with the free Glyco-Immunology webinar series presented by @sitcancer and @SFGlycobiology. Access cutting-edge insights during the second webinar, Glycocheckpoints, Aug. 8. Attendees will identify clinical and translational opportunities and challenges in the field of glyco-immunology. Register: https://ow.ly/4yz750SbfXY
-
-
Learn to successfully implement immunotherapy in clinical practice with a Certificate in #Cancer #Immunotherapy from SITC. All modules are approved for CME, CNE, CPE, & MOC credit. Register today: https://lnkd.in/eeCFCV2m
-
-
The #SITC 2024 Tumor Infiltrating Lymphocytes (#TIL) Symposium Pre-Conference Program will be held on Nov. 6, 2024. This program provides an opportunity for an in-depth discussion on a specific topic in the field of #IO and will provide an overview of the path to approval for TIL #therapy, current #clinical management, and the impact of recent #FDA-approved #therapies while exploring next generation TIL and innovative pre-clinical development. Save up to $200 on Regular Registration Rates by registering by Aug. 14: go.sitcancer.org/3SkAKFH Organizers: Chantale Bernatchez, PhD of The Cell Therapy Manufacturing Center, Stephanie Goff, MD, FACS of the National Cancer Institute, and Shari Pilon-Thomas, PhD of H. Lee Moffitt Cancer Center and Research Institute.
-